A Case Series of Survival Outcomes in Patients with Advanced-stage IIIb/IV Non-small-cell Lung Cancer Treated with HangAm-Plus
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Objectives: Non-small-cell lung cancer (NSCLC) represents approximately 80% of all lung cancers. Unfortunately, at their time of diagnosis, most patients have advanced to unresectable disease with a very poor prognosis. The oriental herbal medicine HangAm-Plus (HAP) has been developed for antitumor purposes, and several previous studies have reported its therapeutic effects. In this study, the efficacy of HAP was evaluated as a third-line treatment for advanced-stage IIIb/IV NSCLC. Methods: The study involved six patients treated at the East-West Cancer Center (EWCC) from April 2010 to October 2011. Inoperable advanced-stage IIIb/IV NSCLC patients received 3,000 or 6,000 mg of HAP on a daily basis over a 12-week period. Computed tomography (CT) scans were obtained from the patients at the time of the initial administration and after 12weeks of treatment. We observed and analyzed the patients overall survival (OS) and progression-free survival (PFS). Results: Of the six patients, three expired during the study,and the three remaining patients were alive as of October 31,2011. The OS ranged from 234 to 512 days, with a median survival of 397 days and a one-year survival rate of 66.7%. In the 12-week-interval chest CT assessment, three patients showed stable disease (SD), and the other three showed progressive disease (PD). The PFS of patients ranged from 88 to 512 days,the median PFS being 96 days. Longer OS and PFS were correlated with SD. Although not directly comparable, the OS and the PFS of this study were greater than those of the docetaxel or the best supportive care group in other studies. Conclusion: HAP may prolong the OS and the PFS of inoperable stage IIIb/IV NSCLC patients without significant adverse effects. In the future, more controlled clinical trials with larger samples from multi-centers should be conducted to evaluate the efficacy and the safety of HAP.
Abstract
Background and Objectives: Non-small-cell lung cancer (NSCLC) represents approximately 80% of all lung cancers. Unfortunately, at their time of diagnosis, most patients have advanced to unresectable disease with a very poor prognosis. The oriental herbal medicine HangAm-Plus (HAP) has been developed for antitumor purposes, and several previous studies have reported its therapeutic effects. In this study, the efficacy of HAP was evaluated as a third-line treatment for advanced-stage IIIb/IV NSCLC. Methods: The study involved six patients treated at the East-West Cancer Center (EWCC) from April 2010 to October 2011. Inoperable advanced-stage IIIb/IV NSCLC patients received 3,000 or 6,000 mg of HAP on a daily basis over a 12-week period. Computed tomography (CT) scans were obtained from the patients at the time of the initial administration and after 12weeks of treatment. We observed and analyzed the patients overall survival (OS) and progression-free survival (PFS). Results: Of the six patients, three expired during the study,and the three remaining patients were alive as of October 31,2011. The OS ranged from 234 to 512 days, with a median survival of 397 days and a one-year survival rate of 66.7%. In the 12-week-interval chest CT assessment, three patients showed stable disease (SD), and the other three showed progressive disease (PD). The PFS of patients ranged from 88 to 512 days,the median PFS being 96 days. Longer OS and PFS were correlated with SD. Although not directly comparable, the OS and the PFS of this study were greater than those of the docetaxel or the best supportive care group in other studies. Conclusion: HAP may prolong the OS and the PFS of inoperable stage IIIb/IV NSCLC patients without significant adverse effects. In the future, more controlled clinical trials with larger samples from multi-centers should be conducted to evaluate the efficacy and the safety of HAP.
참고문헌 (30)
- The global burden of disease: 2004 Update, "World Health Organization.", World Health Organization, 12~13 (2008)
- Ferlay J., "Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008", Int J Cancer, 127(12), pp.2893~2917 (2010)
- Parkin DM., "Global cancer statistics, 2002", CA Cancer J Clin, 55(2), pp.74~108 (2005)
- Ramalingam S., "Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions", Oncologist, 13(Suppl 1), pp.5~13 (2008)
- "Types of lung cancer"[URL]
- Jemal A., "Cancer statistics, 2005", CA Cancer J Clin, 55(1), pp.10~30 (2005)
- Govindan R., "The Washington manual of oncology. 2nd ed", pp.134~142 (2007), Lippincott Williams & Wilkins
- Cho JH., "Clinical study in 320 cases for cancer patients on the effect Hangamdan", Collect Dissert Daejeon University, 12(2), pp.157~175 (2004)
- Choi BL., "The clinical study in 62 cases for lung cancer patients on the effects by Hangamdan", Collect Dissert Daejeon University, 10(1), pp.121~131 (2001)
- Yoo HS., "The clinical study in 105 cases for stomach cancer patients on the effects by Hangamdan", Hyehwa Med, 9(2), pp.7~25 (2000)
- Lee YY., "The clinical study in 83 cases for colorectal cancer patients on the effects by Hangamdan", J of Kor Oriental Oncology, 6(1), pp.165~180 (2000)
- 한성수, "항암단을 투여 받은 림프절 외 변연부 B세포 림프종 환자에 대한 증례보고", 대한한방내과학회지, 29(3), pp.810~818 (2008), 대한한방내과학회
- 방선휘, "림프절 전이를 동반한 췌장암환자 1례에 대한 보고", 대한한방내과학회지, 28(4), pp.948~955 (2007), 대한한방내과학회
- 방지영, "Analysis of anti-angiogenic mechanism of HangAmDan-B (HAD-B), a Korean traditional medicine, using antibody microarray chip", BioChip Journal, 4(4), pp.350~355 (2010), 한국바이오칩학회
- 김원재, "Inhibition of cell motility and invasion by HangAmDan-B in NCI-H460 human non-small cell lung cancer cells", ONCOLOGY REPORTS, 26(6), pp.1601~1608, PROFESSOR D A SPANDIDOS
- 유승후, "항암단을 투여한 재발성 편평상피폐암 환자에 대한 7년간의 추적조사", 대한한방내과학회지, 28(2), pp.387~392 (2007), 대한한방내과학회
- 유화승, "Prospective analysis on survival outcomes of non-small cell lung cancer stages over IHb treated with HangAm-Dan", Chinese Journal of Lung Cancer, 13(11), pp.1009~1015, Chinese Anticancer Association
- Eisenhauer EA., "New response evaluation criteria in solid tumours : Revised RECIST guideline(version 1. 1)", Eur J Cancer, 45(2), pp.228~247 (2009)
- Oken MM., "Toxicity and response criteria of the Eastern Cooperative Oncology Group", Am J Clin Oncol, 5(6), pp.649~655 (1982)
- Gill S., "Endpoints for adjuvant therapy trials : has the time come to accept disease-free survival as a surrogate endpoint for overall survival?", Oncologist, 11(6), pp.624~629 (2006)
- "Common Terminology Criteria for Adverse Events, Version 3.0"[URL]
- Pfister DG., "American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline : update 2003", J Clin Oncol, 22(2), pp.330~353 (2004)
- Driscoll JJ., "Overall survival : still the gold standard : why overall survival remains the definitive end point in cancer clinical trials", Cancer J, 15(5), pp.401~405 (2009)
- Mandrekar SJ., "Endpoints in phase II trials for advanced non-small cell lung cancer", J Thorac Oncol, 5(1), pp.3~9 (2010)
- Shepherd FA., "Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy", J Clin Oncol, 18(10), pp.2095~2103 (2000)
- Schiller JH., "Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer", N Engl J Med, 346(2), pp.92~98 (2002)
- Socinski MA., "The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer", Respir Care Clin N Am, 9(2), pp.207~236 (2003)
- Noble J., "Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer : a systematic review and practice guideline", J Thorac Oncol, 1(9), pp.1042~1058 (2006)
- Hotta K., "Relationship between response and survival in more than 50, 000 patients with advanced non-smallcell lung cancer treated with systemic chemotherapy in 143 phase III trials", J Thorac Oncol, 2(5), pp.402~407 (2007)
- Stinchcombe TE., "Considerations for secondline therapy of non-small cell lung cancer", Oncologist, 13(Suppl1), pp.28~36 (2008)